Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 3Unknown 2Recruiting 2Completed 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Lung Neoplasms 6Solid Tumor 1Small Cell Lung Carcinoma 1Resectable Non-small Cell Lung Cancer 1Recurrence 1Rare Tumour 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1NSCLC 1Meningeal Carcinomatosis 1Brain Neoplasms 1

Interventions

Radiotherapy 4aflutinib 3Saline Solution 3Radiosurgery 3pembrolizumab 2Temozolomide 2Receptors, Interleukin-8B 2Pemetrexed 2Memantine 2Magnetic Resonance Spectroscopy 2Indocyanine Green 2Dexmedetomidine 2Cyclophosphamide 2Carboplatin 2Blood Specimen Collection 2Bevacizumab 2vorasidenib 1urinastatin 1trastuzumab deruxtecan 1tovorafenib 1sacituzumab govitecan 1posaconazole 1peginterferon alfa-2b 1osimertinib 1neratinib 1montelukast 1gallium maltolate 1fludarabine 1dalpiciclib 1asciminib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Brain Neoplasms × osimertinib × Clear all
NCT06319950 2024-03-20

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Taizhou Hospital

Phase 2 Not yet recruiting
255 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡